Skip to main content
Publish date:

Thursday's Health Winners & Losers

Targeted Genetics soars.

Targeted Genetics

(TGEN) - Get Tecogen Inc. Report

surged after it narrowed its third-quarter loss from a year ago. The biotech company lost $3.2 million, or 32 cents a share, in the latest quarter, compared with a loss of $5.7 million, or 66 cents a share, for the same period in 2005. Revenue for the three months ended Sept. 30 was $2 million, up from $1.5 million a year ago. Shares were soaring 31% to $3.32.

Isis Pharmaceuticals


was on the rise after the company was the subject of positive research from a Wall Street firm. Cowen & Co. initiated coverage of Isis with an outperform rating, lifting its stock 12.8% to $10.38, a 52-week high.

King Pharmaceuticals

TheStreet Recommends


reported third-quarter profits and revenue that fell from last year, but the results still beat estimates. Shares of King were higher by 3.2% to $16.25. For the three months ended Sept. 30, King earned 44 cents a share, excluding special items, on revenue of $491.7 million. Analysts had predicted earnings of 38 cents and revenue of $469.3 million. King earned $90.4 million, or 37 cents a share, after factoring in all items and costs. Last year, it earned $121.9 million, or 50 cents a share, on revenue of $518 million.

PainCare Holdings


plunged after it swung to a loss in the most recent third quarter. Revenue rose 6.3% to $22.2 million, but PainCare lost $2.2 million, or 3 cents a share, reversing last year's profit of $9.4 million, or 15 cents a share. Excluding items, the company would have lost $213,000 vs. earnings of $4.3 million a year ago. Shares of PainCare were dropping 25% to $1.09.



sank after the medical-device firm cut its fourth-quarter guidance. The company earned $6.7 million, or 26 cents a share, for the quarter ended Sept. 30, reversing the year-ago loss of $1.4 million, or 6 cents a share. Revenue rose 49% from a year ago to $53.8 million. However, the company expects to lose 5 cents to 9 cents a share for the fourth quarter on revenue of around $55 million. Analysts were looking for a 26-cent profit on revenue of $64 million. Shares slumped 21% to $28.50.